Answers are grounded in this paper and cite their sources.
Momordica charantia L. is traditionally used for the management of splenomegaly, although empirical evidence supporting this ethnomedical indication remains limited. This study primarily investigated the traditional fresh leaf/stem infusion and, comparatively, related M. charantia preparations in a cadmium chloride (CdCl2)-induced murine model of splenic injury. Ninety-six Swiss mice were allocated to eight groups, with terminal assessments on Days 1, 7, and 9; CdCl2 was administered on Day 4. Splenic outcomes included absolute and relative spleen mass and qualitative histopathology. Phytochemical profiling was performed by ultra-performance liquid chromatography coupled to high-resolution mass spectrometry (UPLC-HRMS), and radical-scavenging activity was assessed using ABTS and DPPH assays. At Day 9, the traditional fresh leaf/stem infusion showed the strongest and most consistent treatment-associated signal, with lower relative and absolute spleen masses than the CdCl2-exposed disease control. Several other preparations showed numerical reductions in absolute spleen mass but did not meet multiplicity-adjusted significance thresholds. UPLC-HRMS revealed diverse features consistent with triterpenoid-, glycoside-, sterol-, and oxygenated lipid-related natural-product classes. These exploratory findings provide experimental support for further investigation of the traditional fresh leaf/stem infusion, while not establishing clinical efficacy against human splenomegaly.
No takes yet. Share an insight, caveat, or question.
Boy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: